Bridging the Translational Divide in Oncology: In Vivo Testing of Chemo-sensitivity

Stefan Sleijfer; Martijn Lolkema

doi:10.1158/1078-0432.CCR-20-1452

Bridging the Translational Divide in Oncology: In Vivo Testing of Chemo-sensitivity

Clin Cancer Res. 2020 Aug 1;26(15):3897-3898. doi: 10.1158/1078-0432.CCR-20-1452. Epub 2020 Jun 1.

Authors

Stefan Sleijfer¹, Martijn Lolkema²

Affiliations

¹ Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
² Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. m.lolkema@erasmusmc.nl.

PMID: 32482905
DOI: 10.1158/1078-0432.CCR-20-1452

Abstract

A study was presented in which sarcomas were microinjected simultaneously with several drugs to study the pharmacodynamic response after resection. This platform may represent a future way of probing efficacy of anticancer agents in the relevant model system: human tumors.See related article by Gundle et al., p. 3958.

Publication types

Comment

MeSH terms

Antineoplastic Agents*
Humans
Sarcoma*
Soft Tissue Neoplasms*
Tumor Microenvironment

Substances

Antineoplastic Agents